Trending: L'Oreal Reports Higher Sales Despite Fears of Market Slowdown
0946 GMT - L'Oreal is among the most mentioned companies across news items over the past 12 hours, according to Factiva data after it posted an increase in first-quarter revenue, shrugging off fears of a slowdown in the beauty market. The French cosmetics giant booked sales of EUR11.24 billion for the first quarter, up 8.3% in reported terms compared with the prior-year period. The increase offers hope, especially after the company posted results for 2023 as a whole that missed analysts' forecasts in a year marked by geopolitical tensions, inflation and a stagnating beauty market in China. Still, Chief Executive Nicolas Hieronimus said he is optimistic on the outlook of the global beauty market and expects L'Oreal to keep outperforming the market. "Amid a noisy few weeks on beauty with fears of a market slowdown, this result should drive a strong positive share reaction," Jefferies analysts say in a note to clients. L'Oreal shares trade 4.6% higher at EUR442.95. Dow Jones & Co. owns Factiva. (andrea.figueras@wsj.com)
(END) Dow Jones Newswires
April 19, 2024 06:02 ET (10:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters